# A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

> **NCT02387216** · PHASE2 · TERMINATED · sponsor: **Elevation Oncology** · enrollment: 153 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- NSCLC
- Adenocarcinoma
- Heregulin

## Interventions

- **DRUG:** MM-121
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02387216
- **Lead sponsor:** Elevation Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-02-01
- **Primary completion:** 2019-01-02
- **Final completion:** 2019-01-02
- **Target enrollment:** 153 (ACTUAL)
- **Why stopped:** Based on the preliminary results seen during interim analysis, which were confirmed in the final analysis, the Sponsor terminated the study
- **Last updated:** 2021-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02387216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02387216, "A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02387216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*